CureVac (CVAC) Competitors

$4.66 0.00 (0.00%)

As of 05/22/2026

CVAC vs. NAMS, TVTX, CRNX, NNNN, and CPRX

Should you buy CureVac stock or one of its competitors? MarketBeat compares CureVac with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CureVac include NewAmsterdam Pharma (NAMS), Travere Therapeutics (TVTX), Crinetics Pharmaceuticals (CRNX), Anbio Biotechnology (NNNN), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.

How does CureVac compare to NewAmsterdam Pharma?

CureVac (NASDAQ:CVAC) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 0 mentions for CureVac. NewAmsterdam Pharma's average media sentiment score of 1.22 beat CureVac's score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
NewAmsterdam Pharma	Positive

CureVac has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
NewAmsterdam Pharma	$22.57M	183.61	-$203.82M	-$1.79	N/A

CureVac has a net margin of 199.92% compared to NewAmsterdam Pharma's net margin of -943.23%. CureVac's return on equity of -23.03% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

CureVac currently has a consensus target price of $6.83, suggesting a potential upside of 46.64%. NewAmsterdam Pharma has a consensus target price of $48.00, suggesting a potential upside of 35.44%. Given CureVac's higher probable upside, analysts clearly believe CureVac is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

17.3% of CureVac shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CureVac beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

How does CureVac compare to Travere Therapeutics?

CureVac (NASDAQ:CVAC) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

CureVac has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Travere Therapeutics	$490.73M	8.42	-$25.55M	-$0.23	N/A

CureVac has a net margin of 199.92% compared to Travere Therapeutics' net margin of -4.00%. CureVac's return on equity of -23.03% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CureVac presently has a consensus price target of $6.83, suggesting a potential upside of 46.64%. Travere Therapeutics has a consensus price target of $47.83, suggesting a potential upside of 7.66%. Given CureVac's higher probable upside, analysts plainly believe CureVac is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Travere Therapeutics had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Travere Therapeutics and 0 mentions for CureVac. Travere Therapeutics' average media sentiment score of 0.51 beat CureVac's score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Travere Therapeutics	Positive

Summary

CureVac beats Travere Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CureVac compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Crinetics Pharmaceuticals currently has a consensus target price of $76.13, indicating a potential upside of 106.86%. CureVac has a consensus target price of $6.83, indicating a potential upside of 46.64%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Crinetics Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

CureVac has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	503.92	-$465.32M	-$5.13	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Crinetics Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Crinetics Pharmaceuticals and 0 mentions for CureVac. Crinetics Pharmaceuticals' average media sentiment score of 0.26 beat CureVac's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Neutral
CureVac	Neutral

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. CureVac's return on equity of -23.03% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
CureVac	199.92%	-23.03%	-19.09%

Summary

Crinetics Pharmaceuticals beats CureVac on 9 of the 17 factors compared between the two stocks.

How does CureVac compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and CureVac (NASDAQ:CVAC) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Anbio Biotechnology had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Anbio Biotechnology and 0 mentions for CureVac. Anbio Biotechnology's average media sentiment score of 0.00 equaled CureVac'saverage media sentiment score.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
CureVac	Neutral

CureVac has a consensus price target of $6.83, indicating a potential upside of 46.64%. Given CureVac's higher probable upside, analysts plainly believe CureVac is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

CureVac has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	540.96	$6.40M	N/A	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to Anbio Biotechnology's net margin of 0.00%. Anbio Biotechnology's return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
CureVac	199.92%	-23.03%	-19.09%

17.3% of CureVac shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Anbio Biotechnology has a beta of 4.71, suggesting that its stock price is 371% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

Anbio Biotechnology and CureVac tied by winning 6 of the 12 factors compared between the two stocks.

How does CureVac compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Catalyst Pharmaceuticals and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Catalyst Pharmaceuticals' score of -1.00 indicating that CureVac is being referred to more favorably in the news media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Negative
CureVac	Neutral

Catalyst Pharmaceuticals currently has a consensus price target of $32.17, indicating a potential upside of 2.90%. CureVac has a consensus price target of $6.83, indicating a potential upside of 46.64%. Given CureVac's higher probable upside, analysts plainly believe CureVac is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.63
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Catalyst Pharmaceuticals has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.50	$214.33M	$1.74	17.97
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to Catalyst Pharmaceuticals' net margin of 37.08%. Catalyst Pharmaceuticals' return on equity of 35.76% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
CureVac	199.92%	-23.03%	-19.09%

Summary

Catalyst Pharmaceuticals beats CureVac on 12 of the 17 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVAC vs. The Competition

Export

Metric	CureVac	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.05B	$3.37B	$6.43B	$12.32B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	6.47	18.91	21.01	25.66
Price / Sales	14.78	329.35	615.84	111.99
Price / Cash	4.73	125.17	43.49	56.67
Price / Book	1.39	7.09	10.37	7.14
Net Income	$175.50M	$24.45M	$3.57B	$335.98M
7 Day Performance	N/A	5.45%	6.01%	3.56%
1 Month Performance	N/A	2.43%	3.52%	2.54%
1 Year Performance	13.94%	62.98%	34.13%	35.05%

CureVac Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880
NAMS NewAmsterdam Pharma	2.7303 of 5 stars	$34.14 -3.7%	$48.00 +40.6%	+101.2%	$4.14B	$22.57M	N/A	4
TVTX Travere Therapeutics	1.5503 of 5 stars	$42.89 +0.7%	$47.83 +11.5%	+180.5%	$3.96B	$490.73M	N/A	460	Positive News
CRNX Crinetics Pharmaceuticals	2.3731 of 5 stars	$34.70 -5.6%	$76.13 +119.4%	+23.7%	$3.88B	$7.70M	N/A	210
NNNN Anbio Biotechnology	0.9309 of 5 stars	$28.15 +4.5%	N/A	N/A	$3.88B	$8.65M	N/A	27	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CureVac (CVAC) Competitors

CVAC vs. NAMS, TVTX, CRNX, NNNN, and CPRX

How does CureVac compare to NewAmsterdam Pharma?

Summary

How does CureVac compare to Travere Therapeutics?

Summary

How does CureVac compare to Crinetics Pharmaceuticals?

Summary

How does CureVac compare to Anbio Biotechnology?

Summary

How does CureVac compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CureVac (CVAC) Competitors

CVAC vs. NAMS, TVTX, CRNX, NNNN, and CPRX

How does CureVac compare to NewAmsterdam Pharma?

Which has more volatility & risk, CVAC or NAMS?

Does the media prefer CVAC or NAMS?

Which has stronger earnings and valuation, CVAC or NAMS?

Is CVAC or NAMS more profitable?

Do analysts prefer CVAC or NAMS?

Do insiders & institutionals hold more shares of CVAC or NAMS?

Summary

How does CureVac compare to Travere Therapeutics?

Which has more risk and volatility, CVAC or TVTX?

Which has better valuation and earnings, CVAC or TVTX?

Is CVAC or TVTX more profitable?

Do institutionals and insiders hold more shares of CVAC or TVTX?

Do analysts prefer CVAC or TVTX?

Does the media prefer CVAC or TVTX?

Summary

How does CureVac compare to Crinetics Pharmaceuticals?

Do analysts rate CRNX or CVAC?

Which has preferable valuation & earnings, CRNX or CVAC?

Which has more volatility and risk, CRNX or CVAC?

Does the media refer more to CRNX or CVAC?

Do insiders and institutionals believe in CRNX or CVAC?

Is CRNX or CVAC more profitable?

Summary

How does CureVac compare to Anbio Biotechnology?

Does the media refer more to NNNN or CVAC?

Do analysts rate NNNN or CVAC?

Which has better earnings and valuation, NNNN or CVAC?

Is NNNN or CVAC more profitable?

Do insiders & institutionals believe in NNNN or CVAC?

Which has more volatility & risk, NNNN or CVAC?

Summary

How does CureVac compare to Catalyst Pharmaceuticals?

Do institutionals and insiders have more ownership in CPRX or CVAC?

Does the media favor CPRX or CVAC?

Do analysts prefer CPRX or CVAC?

Which has more volatility and risk, CPRX or CVAC?

Which has stronger valuation and earnings, CPRX or CVAC?

Is CPRX or CVAC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools